Changes in Hong Kong stocks | Viva Biotech (01873) rose more than 5%, and the volume of two new commercialization projects of Langhua Pharmaceuticals CDMO made an important contribution to the performance

The Zhitong Finance App learned that Viva Biotech (01873) rose by more than 5%. As of press release, it had risen 5.17% to HK$1.425, with a turnover of HK$7.540,500.

According to the news, Viva Biotech recently disclosed its results for the first half of the year. China Merchants Securities indicated that 26H1's revenue was +21.0% year-on-year, mainly due to the important contribution of Langhua Pharmaceuticals' two new commercialization projects. Specifically, 26H1 Langhua Pharmaceutical's revenue was 601 million yuan, +47.0% year-on-year (fixed exchange rate +52.2%). Two major new commercialization projects are progressing steadily. The peptide project has been commercialized and has entered the stocking stage; the small molecule project is in the PPQ production stage and is expected to be commercialized in 2027. Both will be the core driving force for CDMO's continued growth in the next few years.